STAT+: Kyverna Therapeutics plans to submit cell therapy for stiff person syndrome for FDA approval
Stat News • 4/21/2026 – 4/22/2026
Summary
Kyverna Therapeutics plans to submit a one-time cell therapy for stiff person syndrome for FDA approval. In a late-stage trial, the therapy improved mobility and reduced disabilities in patients with this rare disease.
Advertisement
Lindy Score Breakdown (V4.2)
19h
Age
1
Sources
from cluster
6
Hours Since Seen
Final Score11/100
CategoryAntiLindy
StatusActive
Recency Multiplier92% (0.5^6/48)
Hero EligibleYes
Score BreakdownRisk 70
Source Reputation: Low-trust source (4/20 pts)
Consensus: Single source - no independent confirmation yet
Age: Breaking news - too recent to assess longevity
Stories gain Lindy status through source reputation, network consensus, and time survival.
Breaking Similar stories
STAT+: The latest biotech news: RevMed, Roche, Kyverna CAR-T therapy
Stat News • Today
STAT+: Gene therapy trial for deafness adds evidence to drug’s efficacy
Stat News • Today
STAT+: Eli Lilly’s $3.25 billion acquisition of Kelonia Therapeutics caps startup’s tortuous ride
Stat News • 2 days ago
STAT+: Kelonia Therapeutics’ road from floundering to $3 billion
Stat News • 1 day ago
STAT+: Extended use of Nektar Therapeutics drug shows promise in alopecia
Stat News • 2 days ago
STAT+: Key GOP senators push back on Trump’s plan to cut NIH, reorganize HHS
Stat News • Today
STAT+: At AACR, more strong results for Revolution Medicine’s KRAS drug, plus assurance from NCI’s director
Stat News • Today
STAT+: Trump order to advance psychedelic treatments generates excitement — and worries
Stat News • 2 days ago
STAT+: Pharmalittle: We’re reading about a Purdue Pharma settlement, a setback for Merck and Eisai, and more
Stat News • 1 day ago
STAT+: Kennedy hints at coming breakthrough device announcement
Stat News • 1 day ago
Anti-Lindy Similar stories
STAT+: FDA approves Denali Therapeutics drug for Hunter syndrome
Stat News • 4 weeks ago
STAT+: Pharmalittle: We’re reading about Trump tariff plans, FDA’s OK for a Lilly obesity pill, and more
Stat News • 2 weeks ago
STAT+: Trump administration prepares 100% tariffs on some imported drugs
Stat News • 2 weeks ago
STAT+: Kennedy focuses on affordability, combating fraud in Capitol Hill hearings
Stat News • 6 days ago
STAT+: How a four-month FDA delay forced a small biotech company to close its doors
Stat News • 2 weeks ago
STAT+: FDA’s evolving view of what makes a ‘breakthrough’ device
Stat News • 2 weeks ago
STAT+: 7 key issues we’re watching as RFK Jr. faces a Congressional gauntlet
Stat News • 6 days ago
STAT+: Pharmalittle: We’re reading about Trump pushing drug pricing policy, Chinese biotech licensing, and more
Stat News • 3 weeks ago
STAT+: RFK Jr. begins his testimony marathon
Stat News • 6 days ago
STAT+: Beyond detection: In the age of clinical AI, what counts as an FDA ‘breakthrough’ medical device?
Stat News • 2 weeks ago